
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial
Keywords: acute coronary syndromes; antiplatelet therapy; antithrombotic therapy apixaban; ACS; acute coronary syndrome(s); CI; confidence interval; HR; hazard ratio; LVEF; left ventricular ejection fraction; MI; myocardial infarction; MSM; marginal structural mode